Apyx Medical Corporation to Release Third Quarter of Fiscal Year 2026 Financial Results on November 5, 2026

CLEARWATER, Fla., Oct. 22, 2026 (GLOBE NEWSWIRE) -- Apyx Medical Corporation (NASDAQ:APYX) (the “Company” or “Apyx Medical”), the leader in surgical aesthetics marketed and sold as Renuvion® and the AYON Body Contouring System™ (AYON), today announced that its financial results for the third quarter of fiscal year 2026 will be released before markets open on Thursday, November 5th.

GlobeNewsWire • 19 hours ago

SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of Apyx Medical Corporation (NASDAQ: APYX)

NEW YORK, Oct. 22, 2026 /PRNewswire/ -- Purcell & Lefkowitz LLP announces that it is investigating Apyx Medical Corporation (NASDAQ: APYX) on behalf of the company's shareholders.  The investigation seeks to determine whether Apyx Medical Corporation's directors breached their fiduciary duties in connection with recent corporate actions.

PRNewsWire • 17 hours ago

Apyx Medical Corporation to Participate in Upcoming Investor Conferences

CLEARWATER, Fla., Oct. 21, 2026 (GLOBE NEWSWIRE) -- Apyx Medical Corporation (NASDAQ:APYX) (“Apyx Medical;” the “Company”), the leader in surgical aesthetics marketed and sold as Renuvion® and the AYON Body Contouring System™ (AYON), today announced that management will present at the following investor conferences: UBS Global Healthcare Conference – November 9-11, 2026 (Miami, FL) Management will participate in a fireside chat at 10:15am ET and will host one-on-one meetings with investors on Monday, November 9.

GlobeNewsWire • Oct 21, 2026

Apyx Medical Announces New Clinical Study Demonstrating Renuvion®'s Impact on Skin Quality

CLEARWATER, Fla., Sept. 29, 2026 (GLOBE NEWSWIRE) -- Apyx Medical Corporation (NASDAQ:APYX) (“Apyx Medical” or the “Company”), the leader in surgical aesthetics marketed and sold as Renuvion® and the AYON Body Contouring System™ (AYON), today announced results from a prospective clinical study evaluating the effects of Renuvion helium plasma radiofrequency technology on biological markers of skin quality.

GlobeNewsWire • Sep 29, 2026

Apyx Medical Sees GLP-1 Boom Fueling Demand for Renuvion, AYON Body Contouring

Apyx Medical NASDAQ: APYX is positioning its Renuvion technology and newly launched AYON Body Contouring System to address growing demand for surgical aesthetic procedures, a trend CEO Charlie Goodwin said has been reshaped by the increasing use of GLP-1 weight-loss drugs.

MarketBeat • Aug 12, 2026

Apyx Medical Corporation (APYX) Q2 2026 Earnings Call Transcript

Apyx Medical Corporation (APYX) Q2 2026 Earnings Call Transcript

Seeking Alpha • Aug 7, 2026

Apyx Medical Q2 Earnings Call Highlights

Apyx Medical NASDAQ: APYX reported second-quarter revenue growth of 22% as sales in its surgical aesthetics business increased, led by adoption of its AYON Body Contouring System, international generator sales and domestic demand for single-use handpieces.

MarketBeat • Aug 6, 2026

Apyx Medical Corporation Reports Second Quarter 2026 Financial Results

CLEARWATER, Fla., Aug. 06, 2026 (GLOBE NEWSWIRE) -- Apyx Medical Corporation (NASDAQ:APYX) (“Apyx Medical;” the “Company”), the leader in surgical aesthetics marketed and sold as Renuvion® and the AYON Body Contouring System™ (AYON), today reported financial results for its second quarter ended June 30, 2026.

GlobeNewsWire • Aug 6, 2026

Apyx Medical (APYX) Reports Q2 Loss, Beats Revenue Estimates

Apyx Medical (APYX) came out with a quarterly loss of $0.07 per share versus the Zacks Consensus Estimate of a loss of $0.06. This compares to a loss of $0.09 per share a year ago.

Zacks Investment Research • Aug 7, 2026

Apyx Medical Corporation to Participate in the Canaccord Genuity 46th Annual Growth Conference

CLEARWATER, Fla., July 28, 2026 (GLOBE NEWSWIRE) -- Apyx Medical Corporation (NASDAQ:APYX) (“Apyx Medical;” the “Company”), the the leader in surgical aesthetics marketed and sold as Renuvion® and the AYON Body Contouring System™ (AYON), today announced that management will participate in the Canaccord Genuity 46th Annual Growth Conference on Tuesday, August 11, 2026, in Boston, MA.

GlobeNewsWire • Jul 28, 2026